Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05185180 · ClinicalTrials.gov registry record

Effects of Epigenetic Regulation in Chronic Pelvic Pain Syndrome

A clinical trial of Chronic Pelvic Pain, sponsored by Northwestern University.

Active
Registry status
50
Enrollment target
1
Study location

NCT05185180 is a study of Chronic Pelvic Pain that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 50 participants, below the 331-participant average among 8 other Chronic Pelvic Pain trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05185180, a study of Chronic Pelvic Pain, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

This study seeks to identify defects in immune activation or regulation that may affect a subset of patients with CP/CPPS. This subset appears to have a reduced ability to mount a regulatory immune response, while simultaneously eliciting an exaggerated activated immune response. The defects that we demonstrate appear to be linked to altered methylation of genes involved in both immune regulation and immune activation. The aims of this study will provide definitive evidence of a role for epigenetic changes in immune cells in patients with CP/CPPS.

Conditions Studied

Study Locations (1)

Illinois

  • Northwestern Memorial Hospital - Chicago

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-10-11
Est. Completion 2025-12-11

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT05185180

The ClinicalTrials.gov registry entry for NCT05185180 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 8 other Chronic Pelvic Pain trials with a reported enrollment target (85% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Pelvic Pain appearing as the primary indexed condition, and to 0 interventions.

NCT05185180 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05185180 about?

NCT05185180 is a clinical study titled "Effects of Epigenetic Regulation in Chronic Pelvic Pain Syndrome". This study seeks to identify defects in immune activation or regulation that may affect a subset of patients with CP/CPPS. This subset appears to have a reduced ability to mount a regulatory immune response, while simultaneously eliciting an exaggerated activated immune response. The defects that we...

What is the current status of trial NCT05185180?

This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2021-10-11. Estimated completion is 2025-12-11.

What conditions does trial NCT05185180 study?

This clinical trial studies the following conditions: Chronic Pelvic Pain.

Who is sponsoring clinical trial NCT05185180?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05185180 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pelvic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.